the benefits of nivolumab and relatlimab in melanoma
Published 2 years ago • 641 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
6:17
relativity-047: relatlimab, an anti-lag-3 antibody nivolumab in first-line advanced melanoma
-
1:56
2-yr relativity-047: nivolumab relatlimab in previously untreated metastatic/unresectable melanoma
-
2:04
benefits and risks of reinduction ipilimumab/nivolumab in patients with melanoma
-
10:42
what is new in melanoma?
-
3:03
what's the best option in the treatment of melanoma?
-
1:04
the safety of nivolumab for advanced melanoma
-
2:22
adjuvant nivolumab in patents with high-risk resected melanoma
-
3:10
the future of immunotherapy in melanoma
-
1:13
clinical trials investigating the treatment of melanoma
-
1:43
future directions in melanoma
-
6:19
should you treat melanoma with nivolumab and relatlimab (opdualag)?
-
1:12
current trials in the treatment of melanoma
-
1:00
the clinical potential of cellular therapeutics in melanoma
-
7:34
adjuvant therapy for melanoma: nivolumab, pembrolizumab, ipilimumab, dabrafenib and trametinib
-
0:37
what is the best sequence of treatment for metastatic melanoma?
-
1:40
the future of monotherapies in melanoma
-
2:14
immuned: adjuvant nivolumab and ipilimumab increases os in stage iv melanoma
-
2:58
the importance of biomarkers to optimize treatment with immunotherapy for melanoma
-
2:43
clinical & tumor characteristics of patients with recurrent melanoma upon immunotherapy